Published in BMJ on November 13, 1993
Screening for human T cell leukaemia/lymphoma virus among blood donors in Sweden: cost effectiveness analysis. BMJ (1998) 1.12
Safe blood? HTLV-1 infection is crippling. BMJ (1994) 0.83
Safe blood? Saving lives costs money. BMJ (1994) 0.75
In vivo cellular tropism of human T-cell leukemia virus type 1. J Virol (1990) 2.70
Prevalence of antibodies to human T cell leukaemia/lymphoma virus in blood donors in north London. BMJ (1993) 2.07
High human T cell lymphotropic virus type 1 (HTLV-1)-specific precursor cytotoxic T lymphocyte frequencies in patients with HTLV-1-associated neurological disease. J Exp Med (1993) 1.97
Activated, HTLV-1-specific cytotoxic T-lymphocytes are found in healthy seropositives as well as in patients with tropical spastic paraparesis. Virology (1992) 1.94
HTLV-1 infection in tropical spastic paraparesis: lymphocyte culture and serologic response. AIDS Res Hum Retroviruses (1988) 1.74
Screening for prolonged incubation of HTLV-I infection in British and Jamaican relatives of British patients with tropical spastic paraparesis. BMJ (1990) 1.45
Characterization of HTLV-I in vivo infected T cell clones. IL-2-independent growth of nontransformed T cells. J Immunol (1992) 1.16
Dendritic cells infected in vitro with human T cell leukaemia/lymphoma virus type-1 (HTLV-1); enhanced lymphocytic proliferation and tropical spastic paraparesis. Clin Exp Immunol (1993) 1.08
Search for human T-cell leukemia virus type I (HTLV-I) proviral sequences by polymerase chain reaction in the central nervous system tissue of HTLV-I-associated myelopathy. Arch Virol (1992) 1.01
The CD4 (T4) antigen is an essential component of the receptor for the AIDS retrovirus. Nature (1985) 30.47
The T4 gene encodes the AIDS virus receptor and is expressed in the immune system and the brain. Cell (1986) 22.26
Neutralization of human T-lymphotropic virus type III by sera of AIDS and AIDS-risk patients. Nature (1985) 6.65
Variable and conserved neutralization antigens of human immunodeficiency virus. Nature (1987) 5.29
Epitopes of the CD4 antigen and HIV infection. Science (1986) 4.50
Soluble CD4 blocks the infectivity of diverse strains of HIV and SIV for T cells and monocytes but not for brain and muscle cells. Nature (1989) 3.54
Phase I study of an immunomodulatory thalidomide analog, CC-4047, in relapsed or refractory multiple myeloma. J Clin Oncol (2004) 3.37
HIV infection does not require endocytosis of its receptor, CD4. Cell (1988) 2.88
In vivo cellular tropism of human T-cell leukemia virus type 1. J Virol (1990) 2.70
Human immunodeficiency virus infection of monocytic and T-lymphocytic cells: receptor modulation and differentiation induced by phorbol ester. Virology (1987) 2.30
Chronic immune activation and inflammation as the cause of malignancy. Br J Cancer (2001) 2.26
AIDS pathogenesis: HIV envelope and its interaction with cell proteins. Immunol Today (1990) 2.21
Serum insulin-like growth factor-1 is not a useful marker of prostate cancer. BJU Int (1999) 2.14
Novel thalidomide analogues display anti-angiogenic activity independently of immunomodulatory effects. Br J Cancer (2002) 2.03
Tropical spastic paraparesis and human T cell lymphotropic virus type 1 in the United Kingdom. Brain (1989) 2.00
The use of 7-amino actinomycin D in identifying apoptosis: simplicity of use and broad spectrum of application compared with other techniques. Blood (1996) 1.52
Screening for prolonged incubation of HTLV-I infection in British and Jamaican relatives of British patients with tropical spastic paraparesis. BMJ (1990) 1.45
Retinoids cause apoptosis in pancreatic cancer cells via activation of RAR-gamma and altered expression of Bcl-2/Bax. Br J Cancer (2002) 1.44
The relationship between angiogenesis and the immune response in carcinogenesis and the progression of malignant disease. Eur J Cancer (2000) 1.43
Phase I study to determine the safety, tolerability and immunostimulatory activity of thalidomide analogue CC-5013 in patients with metastatic malignant melanoma and other advanced cancers. Br J Cancer (2004) 1.43
Investigator-initiated trials of targeted oncology agents: why independent research is at risk? Ann Oncol (2010) 1.41
Primary non-Hodgkin's lymphoma of the thyroid with bone marrow infiltration at presentation. Clin Oncol (R Coll Radiol) (1995) 1.41
The gp120 envelope of HIV-1 binds peptides in a similar manner to human leukocyte antigens. AIDS (1995) 1.38
Pre-treatment with chemotherapy can enhance the antigenicity and immunogenicity of tumours by promoting adaptive immune responses. Br J Cancer (2009) 1.35
Inactivation of HIV by nonoxynol-9. Lancet (1988) 1.30
Thalidomide and its analogues have distinct and opposing effects on TNF-alpha and TNFR2 during co-stimulation of both CD4(+) and CD8(+) T cells. Clin Exp Immunol (2002) 1.30
HTLV-III serology distinguishes atypical and endemic Kaposi's sarcoma in Africa. Lancet (1985) 1.25
CC-3052: a water-soluble analog of thalidomide and potent inhibitor of activation-induced TNF-alpha production. J Immunol (1998) 1.20
HIV envelope glycoprotein, antigen specific T-cell responses, and soluble CD4. Lancet (1990) 1.16
Seven genomic subtypes of chronic fatigue syndrome/myalgic encephalomyelitis: a detailed analysis of gene networks and clinical phenotypes. J Clin Pathol (2007) 1.14
Priming of human CD4+ antigen-specific T cells to undergo apoptosis by HIV-infected monocytes. A two-step mechanism involving the gp120 molecule. J Clin Invest (1997) 1.14
Concurrent hydatid disease and cryptococcosis in a 16-year-old girl. Med J Aust (1981) 1.11
Review article: immune suppression and colorectal cancer. Aliment Pharmacol Ther (2006) 1.09
Antigen test versus reverse transcriptase assay for detecting HIV. Lancet (1987) 1.09
Reduction in cytokine production in colorectal cancer patients: association with stage and reversal by resection. Br J Cancer (2000) 1.08
Phase I/II study of topical imiquimod and intralesional interleukin-2 in the treatment of accessible metastases in malignant melanoma. Br J Dermatol (2007) 1.08
Dendritic cells infected in vitro with human T cell leukaemia/lymphoma virus type-1 (HTLV-1); enhanced lymphocytic proliferation and tropical spastic paraparesis. Clin Exp Immunol (1993) 1.08
The relevance of HIV env/CD4 interactions to the pathogenesis of acquired immune deficiency syndrome. J Acquir Immune Defic Syndr (1989) 1.07
Cytokines and soluble receptor changes in the transition from primary to early chronic HIV type 1 infection. AIDS Res Hum Retroviruses (1996) 1.07
Human retroviruses and paediatric disease. Arch Dis Child (1987) 1.06
Lymphokine-activated killer cell activity in rheumatoid arthritis. Clin Exp Immunol (1987) 1.05
Isolation of retroviruses from two patients with "common variable" hypogammaglobulinaemia. Lancet (1986) 1.04
Heat shock proteins refine the danger theory. Immunology (2000) 1.04
Inhibition of HIV replication in vitro by fusidic acid. Lancet (1987) 1.03
Coeliac disease presenting with cerebellar degeneration. Postgrad Med J (1991) 1.03
Thalidomide as an emerging immunotherapeutic agent. Immunol Today (1999) 1.02
Immunotherapeutic and antitumour potential of thalidomide analogues. Expert Opin Biol Ther (2001) 1.02
Improving the efficacy of cancer immunotherapy. Eur J Cancer (2009) 1.01
Differential and antagonistic effects of 9-cis-retinoic acid and vitamin D analogues on pancreatic cancer cells in vitro. Br J Cancer (2000) 1.01
Phosphonoformate (foscarnet): a pilot study in AIDS and AIDS related complex. AIDS (1987) 1.01
Abnormal intracellular IL-2 and interferon-gamma (IFN-gamma) production as HIV-1-assocated markers of immune dysfunction. Clin Exp Immunol (1998) 1.00
Immunotherapy of advanced prostate cancer: a phase I/II trial using Mycobacterium vaccae (SRL172). Br J Urol (1998) 1.00
A phase II study of continuous-infusion 5-fluorouracil with cisplatin and epirubicin in inoperable pancreatic cancer. Br J Cancer (1996) 0.99
Toxicity profile of the immunomodulatory thalidomide analogue, lenalidomide: phase I clinical trial of three dosing schedules in patients with solid malignancies. Eur J Cancer (2006) 0.98
Characteristics and growth patterns of human peritoneal mesothelial cells: comparison between advanced epithelial ovarian cancer and non-ovarian cancer sources. J Soc Gynecol Investig (2000) 0.98
Angiogenesis as a biomarker and target in cancer chemoprevention. Lancet Oncol (2001) 0.97
Studies in healthy human T-cell-leukemia lymphoma virus (HTLV-I) carriers from the Caribbean. Int J Cancer (1986) 0.97
The interleukins in acquired disease. Clin Exp Immunol (1988) 0.96
The T4 glycoprotein is a cell-surface receptor for the AIDS virus. Cold Spring Harb Symp Quant Biol (1986) 0.95
Human immunodeficiency viruses: neutralization and receptors. J Acquir Immune Defic Syndr (1988) 0.94
Inhibition of metastatic potential in colorectal carcinoma in vivo and in vitro using immunomodulatory drugs (IMiDs). Br J Cancer (2009) 0.92
Topical imiquimod and intralesional interleukin-2 increase activated lymphocytes and restore the Th1/Th2 balance in patients with metastatic melanoma. Br J Dermatol (2008) 0.92
The correlation between colorectal cancer rates of proliferation and apoptosis and systemic cytokine levels; plus their influence upon survival. Br J Cancer (2006) 0.91
Anti-tumour activity of afatinib, an irreversible ErbB family blocker, in human pancreatic tumour cells. Br J Cancer (2011) 0.91
Human tumour and dendritic cell hybrids generated by electrofusion: potential for cancer vaccines. Biochim Biophys Acta (2000) 0.91
CD40 ligation for immunotherapy of solid tumours. J Immunol Methods (2001) 0.90
Role of flanking variable sequences in antigenicity of consensus regions of HIV gp120 for recognition by specific human T helper clones. Eur J Immunol (1993) 0.90
A search for retrovirus infection in systemic lupus erythematosus and rheumatoid arthritis. Ann Rheum Dis (1988) 0.90
Reduced expression of interleukin-2 receptors in hypogammaglobulinaemia: a possible cause of higher cancer incidence. Lancet (1986) 0.90
Bladder and prostate cancer screening for human papillomavirus by polymerase chain reaction: conflicting results using different annealing temperatures. Br J Biomed Sci (1993) 0.89
Abnormal cytokine profiles in patients with idiopathic dilated cardiomyopathy and their asymptomatic relatives. Heart (1996) 0.88
Infection of B lymphocytes by the human immunodeficiency virus and their susceptibility to cytotoxic cells. Eur J Immunol (1988) 0.88
HTLV-I infection and neurological disease in Rio de Janeiro. J Neurol Neurosurg Psychiatry (1992) 0.87
1-(3-cyano-2,3-dideoxy-beta-D-erythro-pentofuranosyl)thymine (cyanothymidine): synthesis and antiviral evaluation against human immunodeficiency virus. J Med Chem (1989) 0.87
Treatment patterns, outcomes, and resource utilization of patients with metastatic melanoma in the U.K.: the MELODY study. Br J Dermatol (2014) 0.87
A double-blind placebo-controlled phase II trial of thalidomide in asymptomatic HIV-positive patients: clinical tolerance and effect on activation markers and cytokines. AIDS Res Hum Retroviruses (1997) 0.87
Quantitation of HIV-1 activity in tissue culture supernatants: effects of culture condition on syncytial assays and virus production. J Virol Methods (1989) 0.86
Allogeneic murine melanoma cell vaccine: a model for the development of human allogeneic cancer vaccine. Melanoma Res (1996) 0.86
Eosinophilic folliculitis occurring after bone marrow autograft in a patient with non-Hodgkin's lymphoma. Cancer (1994) 0.85
Phase I study of ONO-4007, a synthetic analogue of the lipid A moiety of bacterial lipopolysaccharide. Clin Cancer Res (2000) 0.85
Retinoic acid enhances the cytotoxic effects of gemcitabine and cisplatin in pancreatic adenocarcinoma cells. Pancreas (2001) 0.85
Repertoire breadth of human CD4+ T cells specific for HIV gp120 and p66 (primary antigens) or for PPD and tetanus toxoid (secondary antigens) Hum Immunol (1998) 0.85
Anti-tumour activity against B16-F10 melanoma with a GM-CSF secreting allogeneic tumour cell vaccine. Gene Ther (1999) 0.85
Bleomycin pulmonary toxicity: its relationship to renal dysfunction. Med Pediatr Oncol (1984) 0.85
Immune reconstitution in HAART-treated children with AIDS. Highly Active Anti-Retroviral Therapy. Lancet (1998) 0.85
Allogeneic whole-tumour cell vaccination in the rat model of prostate cancer. BJU Int (2000) 0.84
Role of CD4 in the penetration of cells by HIV. Adv Exp Med Biol (1991) 0.84
Antibody-dependent cell-mediated cytotoxicity: comparison between HTLV-I and HIV-1 assays. AIDS (1988) 0.84
Lenalidomide enhances the anti-prostate cancer activity of docetaxel in vitro and in vivo. Prostate (2011) 0.84
Cellular immunology of HIV-infection. Clin Exp Immunol (1988) 0.83
Dendritic cells are potent antigen-presenting cells for in vitro induction of primary human CD4+ T-cell lines specific for HIV gp120. J Acquir Immune Defic Syndr (1994) 0.83
Tumour necrosis factor (TNF) and TNF-related molecules in HIV-1+ individuals: relationship with in vitro Th1/Th2-type response. Clin Exp Immunol (1998) 0.83
Retroviruses in rheumatoid arthritis. Ann Rheum Dis (1986) 0.83
Evaluation of hypochlorite-releasing disinfectants against the human immunodeficiency virus (HIV). J Hosp Infect (1990) 0.83
Thalidomide analogue CC-3052 reduces HIV+ neutrophil apoptosis in vitro. Clin Exp Immunol (2000) 0.82
Anti-CD4 autoantibodies and screening for anti-idiotypic antibodies to anti-CD4 monoclonal antibodies in HIV-seropositive people. AIDS (1990) 0.82
A randomized phase II trial of SRL172 (Mycobacterium vaccae) +/- low-dose interleukin-2 in the treatment of metastatic malignant melanoma. Melanoma Res (2003) 0.82
Immunomodulatory agents: the cytokines. Eur J Cancer (1994) 0.81